GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acerus Pharmaceuticals Corp (TSX:ASP) » Definitions » Net Cash per Share

Acerus Pharmaceuticals (TSX:ASP) Net Cash per Share : C$-10.13 (As of Sep. 2022)


View and export this data going back to 2009. Start your Free Trial

What is Acerus Pharmaceuticals Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Acerus Pharmaceuticals's Net Cash per Share for the quarter that ended in Sep. 2022 was C$-10.13.

The historical rank and industry rank for Acerus Pharmaceuticals's Net Cash per Share or its related term are showing as below:

TSX:ASP's Price-to-Net-Cash is not ranked *
in the Drug Manufacturers industry.
Industry Median: 10.02
* Ranked among companies with meaningful Price-to-Net-Cash only.

Acerus Pharmaceuticals Net Cash per Share Historical Data

The historical data trend for Acerus Pharmaceuticals's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acerus Pharmaceuticals Net Cash per Share Chart

Acerus Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.65 -13.00 -19.69 -0.78 -5.58

Acerus Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.56 -5.58 -8.02 -9.28 -10.13

Competitive Comparison of Acerus Pharmaceuticals's Net Cash per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Acerus Pharmaceuticals's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acerus Pharmaceuticals's Price-to-Net-Cash Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acerus Pharmaceuticals's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Acerus Pharmaceuticals's Price-to-Net-Cash falls into.



Acerus Pharmaceuticals Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Acerus Pharmaceuticals's Net Cash per Share for the fiscal year that ended in Dec. 2021 is calculated as

Net Cash per Share (A: Dec. 2021 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(2.764-45.652-0)/7.68794
=-5.58

Acerus Pharmaceuticals's Net Cash per Share for the quarter that ended in Sep. 2022 is calculated as

Net Cash per Share (Q: Sep. 2022 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(4.028-82.122-0)/7.70774
=-10.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acerus Pharmaceuticals  (TSX:ASP) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Acerus Pharmaceuticals Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Acerus Pharmaceuticals's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Acerus Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
7025 Langer Drive, Suite 205, Mississauga, ON, CAN, L5N 0E8
Acerus Pharmaceuticals Corp is a specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of branded products that improve patient experience, with a primary focus on the field of men's health. Its foundational product includes NATESTO, a testosterone therapy based on nasal gel technology. The company commercializes its products via its salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.
Executives
Samuel Herschkowitz Director
Edward Joseph Gudaitis Director, Senior Officer
Robert Martin Motz Senior Officer
Borys Chabursky Director
John Mark Lievonen Director
Norma Beauchamp Director
Stephen Robert Gregory Director

Acerus Pharmaceuticals Headlines